Shares of Synairgen soared 373% as drug proving to be effective against COVID-19

Publish your company news

  |   Coronavirus
no img

Shares of Synairgen, a tiny pharmaceutical firm born out of a U.K. university, soared as much as 373 per cent after the company said its experimental drug cut the risk of developing the worst symptoms of COVID-19.

In a clinical trial involving 220 subjects, the probability of a patient requiring ventilation or dying dropped 79 per cent for those who got Synairgen’s SNG001 versus those who received a placebo, the Southampton, England-based company said in a statement.

Those receiving SNG001 also were more than twice as likely to fully recover from the illness, it added.

The inhaled product is a formulation of a naturally occurring protein, known as interferon beta, that Synairgen has previously said may be deficient in those with greater susceptibility to the new coronavirus, such as the elderly or those with heart and lung complications or diabetes.

Shares of Synairgen Plc, a tiny pharmaceutical firm born out of a U.K. university, soared as much as 373 per cent after the company said its experimental drug cut the risk of developing the worst symptoms of COVID-19.

In a clinical trial involving 220 subjects, the probability of a patient requiring ventilation or dying dropped 79 per cent for those who got Synairgen’s SNG001 versus those who received a placebo, the Southampton, England-based company said in a statement.

Those receiving SNG001 also were more than twice as likely to fully recover from the illness, it added.

The inhaled product is a formulation of a naturally occurring protein, known as interferon beta, that Synairgen has previously said may be deficient in those with greater susceptibility to the new coronavirus, such as the elderly or those with heart and lung complications or diabetes.

Synairgen rose 332 per cent to 157.50 pence at 10:10 a.m. London time. The stock’s latest surge takes its year-to-date gain to about 2,581 per cent, giving Synairgen, which trades on London’s AIM venue for growth companies, a market capitalization of about 235.4 million pounds (US$296 million).

“Valuing the COVID-19 opportunity is nigh on impossible,” FinnCap analyst Mark Brewer said in a note to clients, adding that upcoming discussions with regulators should clarify SNG001’s route to market. Finncap is also corporate broker to the company.